Abstract
New pyrazole-based thiazolyl hydrazone derivatives were obtained via the ring closure reaction of 3,5- dimethyl-1H-1-phenylpyrazole-4-carboxaldehyde thiosemicarbazone with 2-bromoacetophenone derivatives. The compounds were investigated for their cytotoxic effects on A549 and NIH3T3 cell lines. Among these compounds, compound 2i bearing a trifluoromethyl substituent can be identified as the most promising anticancer agent against A549 cancer cell lines. Compound 2i exhibited its inhibitory effect on A549 cells with an IC50 value of 0.0316 mM, whereas cisplatin showed its anticancer activity with an IC50 value of 0.01 mM. According to the IC50 values, the inhibitory effect of compound 2i on A549 cells can be considered to be selective when compared with its effect on NIH3T3 cells.
Keywords: Anticancer activity, Hydrazone, Pyrazole, Thiazole.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of New Pyrazole-based Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Volume: 11 Issue: 7
Author(s): Mehlika Dilek Altıntop, Ahmet Ozdemir, Sinem Ilgın and Ozlem Atli
Affiliation:
Keywords: Anticancer activity, Hydrazone, Pyrazole, Thiazole.
Abstract: New pyrazole-based thiazolyl hydrazone derivatives were obtained via the ring closure reaction of 3,5- dimethyl-1H-1-phenylpyrazole-4-carboxaldehyde thiosemicarbazone with 2-bromoacetophenone derivatives. The compounds were investigated for their cytotoxic effects on A549 and NIH3T3 cell lines. Among these compounds, compound 2i bearing a trifluoromethyl substituent can be identified as the most promising anticancer agent against A549 cancer cell lines. Compound 2i exhibited its inhibitory effect on A549 cells with an IC50 value of 0.0316 mM, whereas cisplatin showed its anticancer activity with an IC50 value of 0.01 mM. According to the IC50 values, the inhibitory effect of compound 2i on A549 cells can be considered to be selective when compared with its effect on NIH3T3 cells.
Export Options
About this article
Cite this article as:
Altıntop Dilek Mehlika, Ozdemir Ahmet, Ilgın Sinem and Atli Ozlem, Synthesis and Biological Evaluation of New Pyrazole-based Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents, Letters in Drug Design & Discovery 2014; 11 (7) . https://dx.doi.org/10.2174/1570180811666140226235350
DOI https://dx.doi.org/10.2174/1570180811666140226235350 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews NMR-based Metabolite Profiling of Pancreatic Cancer
Current Metabolomics Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Prevention of VP-16 Resistance by a Disiloxane, SILA409: Effects of SILA409 on the Expression of GRP78 in NCI-H446 Human Small Cell Lung Cancer Cells
Letters in Drug Design & Discovery Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Patent Selections:
Recent Patents on Biotechnology Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?
Current Gene Therapy Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Synthesis and Anticancer Activity of Phthalimido and Naphthalimido Substituted Dihydropyrimidone Conjugates
Letters in Drug Design & Discovery New Target Therapies for Brain Metastases from Breast Cancer
Current Cancer Drug Targets